Department of Breast Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
Department of Plastic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
Int J Mol Sci. 2023 Jul 31;24(15):12253. doi: 10.3390/ijms241512253.
Breast cancer is a common cancer in women and a leading cause of mortality. With the early diagnosis and development of therapeutic drugs, the prognosis of breast cancer has markedly improved. Chemotherapy is one of the predominant strategies for the treatment of breast cancer. Taxanes, including paclitaxel and docetaxel, are widely used in the treatment of breast cancer and remarkably decrease the risk of death and recurrence. However, taxane resistance caused by multiple factors significantly impacts the effect of the drug and leads to poor prognosis. Long noncoding RNAs (lncRNAs) have been shown to play a significant role in critical cellular processes, and a number of studies have illustrated that lncRNAs play vital roles in taxane resistance. In this review, we systematically summarize the mechanisms of taxane resistance in breast cancer and the functions of lncRNAs in taxane resistance in breast cancer. The findings provide insight into the role of lncRNAs in taxane resistance and suggest that lncRNAs may be used to develop therapeutic targets to prevent or reverse taxane resistance in patients with breast cancer.
乳腺癌是女性中常见的癌症,也是导致死亡的主要原因之一。随着早期诊断和治疗药物的发展,乳腺癌的预后明显改善。化疗是治疗乳腺癌的主要策略之一。紫杉醇和多西紫杉醇等紫杉烷类药物广泛用于乳腺癌的治疗,显著降低了死亡和复发的风险。然而,多种因素导致的紫杉烷耐药性显著影响药物的效果,并导致不良预后。长链非编码 RNA(lncRNA)在关键细胞过程中发挥着重要作用,许多研究表明 lncRNA 在紫杉烷耐药性中发挥着重要作用。在这篇综述中,我们系统地总结了乳腺癌中紫杉烷耐药的机制以及 lncRNA 在乳腺癌中紫杉烷耐药中的功能。这些发现为 lncRNA 在紫杉烷耐药中的作用提供了深入的了解,并表明 lncRNA 可能被用于开发治疗靶点,以预防或逆转乳腺癌患者的紫杉烷耐药性。